Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
CC transcript
Quarterly results
Appointed director
|
|
GUIDED THERAPEUTICS INC (GTHP)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/20/2015 |
8-K
| Conference call transcript |
| 05/14/2015 |
8-K
| Quarterly results, Conference call transcript |
| 03/30/2015 |
8-K
| Quarterly results, Conference call transcript|
Docs:
|
"Guided Therapeutics Reports 2014 Results Key Highlights: • 2015 product sales forecast of over $3 million compared to 2014 product sales of $758,000 • Several key markets expected to ramp up screening efforts in 2015 • FDA response on amended LuViva PMA application expected to be imminent Norcross, GA -- Guided Therapeutics, Inc. today announced its operating results for the fourth quarter and year ended December 31, 2014. Revenue and other income for the fourth quarter ended December 31, 2014 was approximately $185,000, including approximately $172,000 in sales of LuViva® Advanced Cervical Scan devices and disposables and $13,000 from contract and grant income. Revenue for the quarter ended December 31, 2013 was comprised of product sales of approximately $53,000 and contract and grant i...",
"Transcript of Conference Call held on March 25, 2015" |
|
| 03/27/2014 |
8-K
| Quarterly results, Conference call transcript|
Docs:
|
"Key Highlights:",
"Transcript of Conference Call held on March 27, 2014",
"Extension for LuViva Advanced Cervical Scan NORCROSS, GA – Guided Therapeutics, Inc. today announced that the company has submitted a letter requesting a face-to-face meeting with the U.S. Food and Drug Administration in the next 60 to 90 days. This letter is in response to the September 6, 2013 letter that the company received from the FDA. Additionally, the FDA has granted the company its requested 180 day extension on the PMA filing to allow time for the meeting to occur. “While we have drafted our responses to questions in the not approvable letter received in September, we feel it is in our best interest to meet with FDA before submission of the official response,” said Gene Cartwright, Chief Executive Officer of Guided Therapeutics. “These face-to-face meetings are an important part..." |
|
| 11/15/2013 |
8-K
| Quarterly results, Conference call transcript |
|
|